October 17, 2022
RegMed Investors’ (RMi) closing bell: support levels are back for the oversold, although with low volume
October 14, 2022
RegMed Investors’ (RMi) closing bell: risk and sentiment have broken through cell and gene therapy equities
October 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector share pricing rides the roller-coaster
October 11, 2022
RegMed Investors’ (RMi) closing bell: an oversold bounce from nowhere to close neutral in my coverage group
October 10, 2022
RegMed Investors’ (RMi) closing bell: “Waiting for Godot” gets replaced by Jerome Powell in the offing
October 7, 2022
RegMed Investors’ (RMi) closing bell: negative reaction
October 6, 2022
RegMed Investors’ (RMi) closing bell: no, good and bad news makes little difference in sector pricing
October 5, 2022
RegMed Investors’ (RMi) closing bell: another I warned you so …
October 4, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector ballooned-up
October 3, 2022
RegMed Investors’ (RMi) closing bell: snap, crackle and a pop
September 30, 2022
RegMed Investors’ (RMi) closing bell: closing out September and Q3 with an algorithmic upside “rule”
September 29, 2022
RegMed Investors’ (RMi) closing bell: another I told you so!
September 28, 2022
RegMed Investors’ (RMi) closing bell: time to make a portfolio buck and seek safety of cash
September 27, 2022
RegMed Investors’ (RMi) closing bell: don’t get use to today’s upside, I believe it’s “transitory”
September 26, 2022
RegMed Investors’ (RMi) closing bell: playing the bounce game after a very brief upside open
September 23, 2022
RegMed Investors’ (RMi) closing bell: a crash and burn in a brutal week
September 22, 2022
RegMed Investors’ (RMi) closing bell: short positions play the market’s volatility
September 21, 2022
RegMed Investors’ (RMi) closing bell: as expected, 0.75 percentage or basis points, let’s be done with the discourse; inflation is NOT going away!
September 20, 2022
RegMed Investors’ (RMi) closing bell: a slasher session as good news becomes bad news
September 16, 2022
RegMed Investors’ (RMi) closing bell: even positive sector news doesn’t matter to share pricing as market craters taking the cell and gene therapy sector with it
September 15, 2022
RegMed Investors’ (RMi) closing bell: musical chairs until the melody stops
September 14, 2022
RegMed Investors’ (RMi) closing bell: catches a full breath after a deep dive in choppy waters
September 13, 2022
RegMed Investors’ (RMi) closing bell: no chicken dinner as sector and indexes got kicked to the floor while inflation numbers become an unequivocal negative for equities
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.